Genomics Reporting Implementation Guide
4.0.0-cibuild - CI Build

Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 4.0.0-cibuild built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions

## : therapuDrug3-interact-smn1-smn2 - TTL Representation

Page standards status: Informative

Raw ttl | Download

    @prefix fhir: <http://hl7.org/fhir/> .
    @prefix loinc: <https://loinc.org/rdf/> .
    @prefix owl: <http://www.w3.org/2002/07/owl#> .
    @prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
    @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
    @prefix sct: <http://snomed.info/id/> .
    @prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

    # - resource -------------------------------------------------------------------

     a fhir:Observation ;
      fhir:nodeRole fhir:treeRoot ;
      fhir:id [ fhir:v "therapuDrug3-interact-smn1-smn2"] ; #
      fhir:meta [
        ( fhir:profile [
    fhir:v "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication"^^xsd:anyURI ;
    fhir:l <http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication>     ] )
      ] ; #
      fhir:text [
    fhir:status [ fhir:v "extensions" ] ;
    fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Observation therapuDrug3-interact-smn1-smn2</b></p><a name=\"therapuDrug3-interact-smn1-smn2\"> </a><a name=\"hctherapuDrug3-interact-smn1-smn2\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-therapeutic-implication.html\">Therapeutic Implication</a></p></div><p><b>status</b>: Final</p><p><b>category</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/observation-category laboratory}\">Laboratory</span>, <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/v2-0074 GE}\">Genetics</span></p><p><b>code</b>: <span title=\"Codes:{http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs therapeutic-implication}\">Therapeutic Implication</span></p><p><b>subject</b>: A Newborn</p><p><b>effective</b>: 2019-04-01</p><p><b>performer</b>: <a href=\"Organization-ExampleOrg.html\">Organization some lab</a></p><p><b>derivedFrom</b>: </p><ul><li><a href=\"Observation-obs1-interact-smn1-smn2.html\">Observation Genetic variant assessment</a></li><li><a href=\"Observation-obs2-interact-smn1-smn2.html\">Observation Genetic variant assessment</a></li></ul><blockquote><p><b>component</b></p><p><b>code</b>: <span title=\"Codes:{http://loinc.org 81259-4}\">Associated phenotype</span></p><p><b>value</b>: <span title=\"Codes:{http://snomed.info/sct 5262007}\">Spinal muscular atrophy (SMA)</span></p></blockquote><blockquote><p><b>component</b></p><p><b>code</b>: <span title=\"Codes:{http://loinc.org 51963-7}\">Medication assessed</span></p><p><b>value</b>: <span title=\"Codes:\">risdiplam (small molecule)</span></p></blockquote><blockquote><p><b>component</b></p><p><b>Related artifact</b>: No display for RelatedArtifact  (type: citation; url: https://pubmed.ncbi.nlm.nih.gov/29614695/)</p><p><b>code</b>: <span title=\"Codes:{http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs conclusion-string}\">Conclusion Text</span></p><p><b>value</b>: Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by the degeneration of alpha motor neurons in the spinal cord, leading to muscular atrophy. SMA is caused by deletions or mutations in the survival motor neuron 1 gene (SMN1). In humans, a nearly identical copy gene, SMN2, is present. Because SMN2 has been shown to decrease disease severity in a dose-dependent manner, SMN2 copy number is predictive of disease severity...The overarching recommendation is that all infants with two or three copies of SMN2 should receive immediate treatment</p></blockquote></div>"^^rdf:XMLLiteral ]
      ] ; #
      fhir:status [ fhir:v "final"] ; #
      fhir:category ( [
        ( fhir:coding [
    fhir:system [
    fhir:v "http://terminology.hl7.org/CodeSystem/observation-category"^^xsd:anyURI ;
    fhir:l <http://terminology.hl7.org/CodeSystem/observation-category>       ] ;
    fhir:code [ fhir:v "laboratory" ]     ] )
      ] [
        ( fhir:coding [
    fhir:system [
    fhir:v "http://terminology.hl7.org/CodeSystem/v2-0074"^^xsd:anyURI ;
    fhir:l <http://terminology.hl7.org/CodeSystem/v2-0074>       ] ;
    fhir:code [ fhir:v "GE" ]     ] )
      ] ) ; #
      fhir:code [
        ( fhir:coding [
    fhir:system [
    fhir:v "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs"^^xsd:anyURI ;
    fhir:l <http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs>       ] ;
    fhir:code [ fhir:v "therapeutic-implication" ]     ] )
      ] ; #
      fhir:subject [
    fhir:display [ fhir:v "A Newborn" ]
      ] ; #
      fhir:effective [
    a fhir:DateTime ;
    fhir:v "2019-04-01"^^xsd:date
      ] ; #
      fhir:performer ( [
    fhir:l fhir:Organization/ExampleOrg ;
    fhir:reference [ fhir:v "Organization/ExampleOrg" ]
      ] ) ; #
      fhir:derivedFrom ( [
    fhir:l fhir:Observation/obs1-interact-smn1-smn2 ;
    fhir:reference [ fhir:v "Observation/obs1-interact-smn1-smn2" ]
      ] [
    fhir:l fhir:Observation/obs2-interact-smn1-smn2 ;
    fhir:reference [ fhir:v "Observation/obs2-interact-smn1-smn2" ]
      ] ) ; #
      fhir:component ( [
    fhir:code [
          ( fhir:coding [
    a loinc:81259-4 ;
    fhir:system [
    fhir:v "http://loinc.org"^^xsd:anyURI ;
    fhir:l <http://loinc.org>         ] ;
    fhir:code [ fhir:v "81259-4" ]       ] )     ] ;
    fhir:value [
    a fhir:CodeableConcept ;
          ( fhir:coding [
    a sct:5262007 ;
    fhir:system [
    fhir:v "http://snomed.info/sct"^^xsd:anyURI ;
    fhir:l <http://snomed.info/sct>         ] ;
    fhir:code [ fhir:v "5262007" ] ;
    fhir:display [ fhir:v "Spinal muscular atrophy (disorder)" ]       ] ) ;
    fhir:text [ fhir:v "Spinal muscular atrophy (SMA)" ]     ]
      ] [
    fhir:code [
          ( fhir:coding [
    a loinc:51963-7 ;
    fhir:system [
    fhir:v "http://loinc.org"^^xsd:anyURI ;
    fhir:l <http://loinc.org>         ] ;
    fhir:code [ fhir:v "51963-7" ] ;
    fhir:display [ fhir:v "Medication assessed" ]       ] )     ] ;
    fhir:value [
    a fhir:CodeableConcept ;
    fhir:text [ fhir:v "risdiplam (small molecule)" ]     ]
      ] [
        ( fhir:extension [
    fhir:url [
    fhir:v "http://hl7.org/fhir/StructureDefinition/workflow-relatedArtifact"^^xsd:anyURI ;
    fhir:l <http://hl7.org/fhir/StructureDefinition/workflow-relatedArtifact>       ] ;
    fhir:value [
    a fhir:RelatedArtifact ;
    fhir:type [ fhir:v "citation" ] ;
    fhir:url [
    fhir:v "https://pubmed.ncbi.nlm.nih.gov/29614695/"^^xsd:anyURI ;
    fhir:l <https://pubmed.ncbi.nlm.nih.gov/29614695/>         ]       ]     ] ) ;
    fhir:code [
          ( fhir:coding [
    fhir:system [
    fhir:v "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs"^^xsd:anyURI ;
    fhir:l <http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs>         ] ;
    fhir:code [ fhir:v "conclusion-string" ]       ] )     ] ;
    fhir:value [
    a fhir:String ;
    fhir:v "Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by the degeneration of alpha motor neurons in the spinal cord, leading to muscular atrophy. SMA is caused by deletions or mutations in the survival motor neuron 1 gene (SMN1). In humans, a nearly identical copy gene, SMN2, is present. Because SMN2 has been shown to decrease disease severity in a dose-dependent manner, SMN2 copy number is predictive of disease severity...The overarching recommendation is that all infants with two or three copies of SMN2 should receive immediate treatment"     ]
      ] ) . #